A major hurdle in organ transplants is the human body itself, as a transplanted organ is usually seen as foreign and attacked by the immune system. — dpa
A new transplant therapy could potentially help patients avoid the need for lifelong anti-rejection drugs, a new study suggests.
Scientists have developed a new technique that involves transplant patients receiving a pioneering therapy made by certain cells that have a role in the body’s immune system.
By receiving both the organ and cells from the same donor, the patients’ immune system appears less likely to reject the new organ, the experts found.
Dendritic cells play an important role in the body’s immune system by helping to launch a response to potential threats.
They also help the immune system tolerate harmless components instead of attacking them.
Using this knowledge, the researchers created a donor-derived regulatory dendritic cell therapy for liver transplant patients.
They theorised that these donor-sourced cells could “teach” the recipient’s immune system to tolerate the new organ.
In an early-stage study, 13 patients were given a single infusion of the dendritic cell therapy a week before their transplant.
They were compared with 40 liver transplant patients who received the usual care, which includes a regimen of anti-rejection (immunosuppressant) drugs.
Immunosuppressants work by dampening down the body’s immune system.
When a person has an organ transplant, they usually need to take these drugs for life to prevent the body’s immune system from attacking the donated organ.
But the drugs come with their own complications, including a higher risk of infection, and kidney and heart toxicity.
In the study published in the journal Science Translational Medicine, the researchers found that there were no differences between the two groups in terms of organ rejection rates.
They said that the cell therapy appeared to be “well tolerated” by the transplant recipients during the year-long trial.
The academics, led by experts at the University of Pittsburgh School of Medicine in the United States, found that the patients who received the donor-derived cell therapy showed a similar drop in “anti-transplant immune responses”, compared with those who received standard immunosuppressive drugs.
This suggests that the new treatment could potentially reduce dependence on immunosuppressive drugs, they said.
“(This) may be conducive to reduced dependence on immunosuppressive drug therapy or immunosuppression withdrawal,” the authors wrote.
The research is still in its early phases with more work to be done, but they said: “Donor-derived regulatory dendritic cells infusion is a promising candidate adoptive cell therapy for drug minimisation and tolerance induction in solid organ transplantation.”
The idea for the therapy came about after it emerged that an eight-year-old girl in the United Kingdom was able to live a life without immunosuppressant drugs following a kidney transplant.
Aditi Shankar’s immune system was “reprogrammed” after a stem cell transplant, and as a result, her body accepted a donor kidney as its own.
Because the bone marrow transplant and kidney came from the same donor – Aditi’s mother – the new kidney is working without the need for drugs that stop the body from rejecting a donated organ.
Aditi stopped taking immunosuppressant drugs a month after her surgery at Great Ormond Street Hospital in London. – PA Media/dpa
